NeuroInsights unveils expanded fourth edition of comprehensive market
analysis and strategic investment report at Neurotech Industry Conference
SAN FRANCISCO and BOSTON, May 8 /PRNewswire/ -- NeuroInsights, the
neurotech market authority, announced today the release of the
organization's fourth annual comprehensive investment guide and market
analysis of the global neurological disease and psychiatric illness
markets. Unveiled during the annual Neurotech Industry Investing and
Partnering Conference in Boston, this 400-page report enables investors,
companies and governments to assess opportunities, calculate risks and
understand the dynamics of this continually changing market.
The Neurotechnology Industry 2008 Report: Drugs, Devices and
Diagnostics for the Brain and Nervous System tracks market movements that
help guide strategic business development and investment decisions in
neurotech. This year's report provides an in-depth look at more than 16
brain and nervous system disorders and treatments in development at over
500 public and private companies, including: Alzheimer's disease,
addiction, ADHD, anxiety, depression, epilepsy, migraine, mild cognitive
impairment, multiple sclerosis, obesity, pain, Parkinson's disease,
schizophrenia, age-related macular degeneration, sensory disorders, sleep
disorders, stroke and traumatic brain injury. Corporate financing, market
activity, growth drivers and global industry conditions that make up the
obstacles and opportunities facing the industry are fully assessed with
detailed insights.
Specific findings from the Neurotechnology Industry 2008 Report show
that in 2007:
-- Brain-related illnesses represent the largest unmet medical market with
two billion people worldwide
-- Venture capital investment in neurotechnology reached an all-time high
at $1.77 billion
-- More than 250 investors participated in neurotech financings
-- Global neurotech industry revenues rose 8.3% to $130.5 billion
-- Neuropharmaceuticals recorded revenues of $109 billion and 8% annual
growth
-- Neurodevices recorded revenues of $5.5 billion and 22% annual growth
-- Neurodiagnostics recorded revenues of $16 billion and 6% annual growth
"The neurotechnology industry made substantial gains in 2007, which has
continued into 2008," said Casey Lynch, Managing Director of NeuroInsights.
"Commercial neuroscience represents one of the fastest-growing and
critically needed sectors of the healthcare industry. In 2007, this was
underscored in the launch of several important industry initiatives,
including the creation of the NASDAQ NeuroInsights Neurotech Index in
September."
Specific milestones from the report were presented during
NeuroInsights' annual Neurotech Industry Investing and Partnering
Conference, hosted in partnership with the Neurotechnology Industry
Organization. This conference, being held at the Westin Copley Place in
Boston today and tomorrow, is the premier global forum where investors,
executives, entrepreneurs, scientists and others involved in the
development of new treatments and diagnostics for the brain and nervous
system come together to shape the future of their organization and the
industry.
The Neurotechnology Industry 2008 Report: Drugs, Devices and
Diagnostics for the Brain and Nervous System is now available for purchase
in book or digital format at
http://www.neuroinsights.com/marketreports/marketreport2008.html
About NeuroInsights
NeuroInsights is the world's leading neurotechnology research and
advisory firm. As the neurotechnology market authority, NeuroInsights helps
investors, industry and society understand and profit from the rapid growth
in drugs, devices and diagnostics for the brain and nervous system.
NeuroInsights provides market reports, investment information, industry
events and strategic advisory services to venture funds, startups,
corporations, governments and financial institutions. For more information,
visit http://www.neuroinsights.com.
Contact:
Casey Lynch
NeuroInsights
(415) 229-3225
casey@neuroinsights.com
SOURCE NeuroInsights
 back to top
Related links:
http://www.neuroinsights.com
CONTACT:
Casey Lynch of NeuroInsights,
+1-415-229-3225, casey@neuroinsights.com
|
